Breaking News Instant updates and real-time market news.

V

Visa

$108.99

0.881 (0.81%)

, MA

MasterCard

$148.24

1.5 (1.02%)

10:23
10/13/17
10/13
10:23
10/13/17
10:23

On The Fly: Top five analyst initiations

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Visa (V) and MasterCard (MA) were initiated with an Overweight at Stephens. 2. Acuity Brands (AYI) initiated with a Sector Weight at KeyBanc. 3. Williams-Sonoma (WSM) and RH (RH) were initiated with a Hold at Stifel. 4. Signature Bank (SBNY) assumed with a Neutral at Piper Jaffray. 5. NewLink Genetics (NLNK) initiated with a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

V

Visa

$108.99

0.881 (0.81%)

MA

MasterCard

$148.24

1.5 (1.02%)

AYI

Acuity Brands

$163.34

-2.0991 (-1.27%)

WSM

Williams-Sonoma

$50.11

1.22 (2.50%)

RH

RH

$78.88

1.68 (2.18%)

SBNY

Signature Bank

$124.56

-1.12 (-0.89%)

NLNK

NewLink Genetics

$11.25

0.29 (2.65%)

  • 22

    Oct

  • 25

    Oct

  • 31

    Oct

  • 29

    Nov

  • 05

    Jan

V Visa
$108.99

0.881 (0.81%)

10/11/17
10/11/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) upgraded to Buy from Hold at Jefferies with analyst Jeffrey Holford saying J&J's Pharma division is "under-modeled" by analysts and will drive above-consensus revenue and earnings growth. 2. Visa (V) and MasterCard (MA) were upgraded to Outperform from Market Perform at Wells Fargo. 3. Colgate-Palmolive (CL) upgraded to Buy from Hold at SunTrust with analyst William Chappell saying the recent three consecutive quarters of weak results is an "anomaly" given the company's long term track record of consistent mid-single-digit or higher organic growth. 4. AbbVie (ABBV) upgraded to Outperform from Market Perform at Cowen with analyst Steve Scala saying AbbVie "showed the best" of all the companies at Cowen's Annual Therapeutics Conference last week. 5. PayPal (PYPL) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst James Faucette calling it among the few large companies that can deliver high-teens revenue and 20% EPS growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/11/17
WELS
10/11/17
UPGRADE
Target $160
WELS
Outperform
MasterCard upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Donald Fandetti took over coverage of MasterCard (MA) with an Outperform rating and $160 price target, up from the firm's prior rating of Market Perform and $130 price target. Fandetti, who believes MasterCard is well positioned to deliver roughly 20% EPS growth, has a near-term preference for Visa (V), citing valuation and Visa Europe.
10/10/17
WELS
10/10/17
UPGRADE
Target $120
WELS
Outperform
Visa upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo transferred coverage of Visa to Donald Fandetti who upgraded the stock to Outperform form Market Perform with a $120 price target. Fandetti believes Visa's earnings model for the networks remains very much intact and are supported by pricing power and significant capital return. He expects positive earnings revisions in 2018 and for Visa Europe integration to ultimately drive expense synergies as processing systems are consolidated.
10/13/17
SPHN
10/13/17
INITIATION
Target $125
SPHN
Overweight
Visa initiated with an Overweight at Stephens
Stephens analyst Brett Huff started Visa (V) with an Overweight rating and $125 target, saying he thinks the company and peer MasterCard (MA) can beat near- and medium-term consensus expectations and can support higher multiples. While he also started MasterCard with an Overweight rating, he likes Visa "a bit better," partially since he sees Visa Europe as a meaningful revenue and profit growth driver, Huff tells investors.
MA MasterCard
$148.24

1.5 (1.02%)

10/13/17
SPHN
10/13/17
INITIATION
Target $166
SPHN
Overweight
MasterCard initiated with an Overweight at Stephens
Stephens analyst Brett Huff started MasterCard with an Overweight rating and $166 price target, saying he sees secular trends driving card net revenue growth for "many year" ahead.
AYI Acuity Brands
$163.34

-2.0991 (-1.27%)

10/13/17
KEYB
10/13/17
INITIATION
KEYB
Sector Weight
Acuity Brands initiated with a Sector Weight at KeyBanc
KeyBanc analyst Daniel Baksht started Acuity Brands with a Sector Weight rating saying he sees the shares as fully valued.
10/09/17
WOLF
10/09/17
DOWNGRADE
WOLF
Peer Perform
Acuity Brands downgraded to Peer Perform from Outperform at Wolfe Research
10/05/17
ROTH
10/05/17
NO CHANGE
Target $130
ROTH
Sell
Acuity Brands price target lowered to $130 from $150 at Roth Capital
Roth Capital analyst Craig Irwin lowered his price target for Acuity Brands to $130 from $150 as he remains cautious on rebounding growth, as past volumes have benefited from an aggressive acquisition program, and a Y2-Y5 acquisition growth tail, where this benefit has clearly disappeared. The analyst sees of Acuity Brands as an underperforming low- to mid-single-digit grower with spotty execution. He reiterates a Sell rating on the shares.
10/10/17
OPCO
10/10/17
NO CHANGE
Target $200
OPCO
Outperform
Acuity Brands price target lowered to $200 from $230 at Oppenheimer
Oppenheimer analyst Christopher Glynn lowered his price target for Acuity Brands to $200 from $230 on valuation. The analyst reiterates an Outperform rating on the shares.
WSM Williams-Sonoma
$50.11

1.22 (2.50%)

07/14/17
LEHM
07/14/17
NO CHANGE
Target $40
LEHM
Underweight
Amazon can be big threat to Williams-Sonoma, says Barclays
Following an analysis that compares product overlap, Barclays analyst Matthew McClintock believes Amazon.com (AMZN) can be a "considerable threat" to Williams-Sonoma (WSM). The analyst estimates that 50% of the first 10 "Top Rated" items by category listed on Williams-Sonoma's website have exact overlap with Amazon. Further, McClintock found that Amazon beat on price on 50 of the 69 items, or 73%. The analyst says he's bearish on Williams-Sonoma following his analysis. In a research note titled "The Next AMZN Shoe to Drop?", he keeps an Underweight rating on the shares with a $40 price target.
08/24/17
JPMS
08/24/17
NO CHANGE
Target $60
JPMS
Overweight
Williams-Sonoma Q2 report dented bear case, says JPMorgan
JPMorgan analyst Christopher Horvers said Williams-Sonoma's Q2 report included a "long list of positives," and put another, "arguably larger," dent in the bear case built on predictions of an impending margin reset and the loss of share at the Pottery Barn brand. The analyst, who expects further acceleration in PB, PB Kids, and PBTeen brand comps and thinks the overall operating margin profile should improve, keeps an Overweight rating on Williams-Sonoma shares, though he lowered his price target to $60 from $64.
10/12/17
STFL
10/12/17
INITIATION
Target $54
STFL
Hold
Williams-Sonoma initiated with a Hold at Stifel
Stifel analyst John Baugh started Williams-Sonoma with a Hold rating and $54 price target, citing struggles in the company's key Pottery Barn brand, margin pressures from shipping and a higher mix of lower priced products.
10/12/17
FBCO
10/12/17
DOWNGRADE
Target $44
FBCO
Underperform
Williams-Sonoma downgraded to Underperform from Neutral at Credit Suisse
Credit Suisse analyst Seth Sigman downgraded Williams-Sonoma to Underperform with an unchanged price target of $44. The analyst expects the company's investments to remain elevated. The cost of doing business in the sector continues to rise, which may pressure Williams-Sonoma's margins more than what is reflected in estimates and the stock, Sigman tells investors in a research note. He notes the shares are up 18% from their August low.
RH RH
$78.88

1.68 (2.18%)

10/12/17
STFL
10/12/17
INITIATION
Target $75
STFL
Hold
RH initiated with a Hold at Stifel
Stifel analyst John Baugh started RH with a Hold rating and $75 price target, citing valuation and the stock's volatility.
09/26/17
DBAB
09/26/17
UPGRADE
Target $84
DBAB
Buy
RH upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Adam Sindler upgraded RH to Buy and raised his price target for the shares to $84 from $80. The analyst has a favorable view of both the company's fundamentals and the risk/reward at current share levels. He believes the retailer can stabilize gross margins in the 36%-37% range, above his previous estimates, given the company's inventory optimization work and supply chain initiatives.
09/07/17
09/07/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. RH (RH) upgraded to Buy from Neutral at Buckingham with analyst Kelly Halsor saying second quarter results changed is skeptical view of the turnaround story and he now expects a meaningful margin inflection in second half 2017 and beyond. 2. Generac (GNRC) upgraded to Neutral from Underperform at BofA/Merrill with analyst Ross Gilardi upgraded Generac ahead of Hurricane Irma and pending details into the company's investor day. 3. TJX (TJX) upgraded to Buy from Neutral at Northcoast analyst Nicholas Mitchell citing what he views as an attractive valuation, "plenty of runway" to grow sales through share capture and new store growth and his positive view of its new HomeSense concept. 4. Praxair (PX) upgraded to Positive from Neutral at Susquehanna with analyst Don Carson citing his pro-forma valuation following its merger with Linde. 5. PacWest Bancorp (PACW) upgraded to Buy from Neutral at DA Davidson with analyst Gary Tenner citing valuation following the recent pullback in the shares. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/11/17
LOOP
10/11/17
NO CHANGE
Target $65
LOOP
Hold
RH price target raised to $65 on 'growing optimism' at Loop Capital
Loop Capital analyst Anthony Chukumba said he is encouraged to see that RH has repaid its $100M second lien term loan, noting the "onerous" interest rate it held. He raised his price target on RH shares to $65 from $55 to reflect his "growing optimism" that the company has begun turning a corner, though he keeps a Hold rating on the stock, which he notes has outperformed recently.
SBNY Signature Bank
$124.56

-1.12 (-0.89%)

09/20/17
09/20/17
DOWNGRADE
Target $126

Neutral
Signature Bank downgraded to Neutral at Wedbush
As previously reported, Wedbush analyst David Chiaverini downgraded Signature Bank to Neutral from Outperform, citing his expectation for "significant pressure" on the company's net interest margin in coming quarters as well as the competitive environment negatively impacting loan growth. The analyst also lowered his price target on the shares to $126 from $157.
10/13/17
PIPR
10/13/17
INITIATION
Target $140
PIPR
Neutral
Signature Bank assumed with a Neutral at Piper Jaffray
Piper Jaffray analyst Matthew Breese assumed coverage of Signature Bank with a Neutral rating and lowered his price target for the shares to $140 from $150. The analyst sees a challenging loan growth environment for the bank in the near-term.
09/20/17
WEDB
09/20/17
DOWNGRADE
WEDB
Neutral
Signature Bank downgraded to Neutral from Outperform at Wedbush
09/11/17
HOVD
09/11/17
UPGRADE
HOVD
Market Perform
Signature Bank upgraded to Market Perform from Underperform at Hovde Group
NLNK NewLink Genetics
$11.25

0.29 (2.65%)

09/11/17
STFL
09/11/17
NO CHANGE
Target $29
STFL
Buy
NewLink Genetics price target raised to $29 from $14 at Stifel
Stifel analyst Stephen Willey believes recently-updated melanoma data from both NewLink Genetics' (NLNK) phase 2 indoximod program and Incyte (INCY) and Merck's (MRK) ESMO presentation confirm IDO inhibitors are more-than-likely synergizing with PD-1 inhibition, adding that NewLink's drug appears to yield "slightly-better efficacy" in "slightly-healthier" patients. He increased his price target on NewLink to $29 from $14 to reflect favorable risk adjustments and higher melanoma sales estimates and keeps a Buy rating on the stock.
09/13/17
CANT
09/13/17
NO CHANGE
Target $26
CANT
Overweight
Cantor still likes NewLink's indoximod amid concerns over data
Cantor Fitzgerald analyst Mara Goldstein in a research note yesterday afternoon attributed the selloff in shares of NewLink Genetics to the market digesting the updated indoximod dataset. The stock traded off on concerns that non-evaluable patients were not included, but this was known based on the press release on September 7, Goldstein told investors. The data represented the 51 non-ocular melanoma patients reported on at AACR 2017, and the analyst expects the final data for all patients at some point. She still likes indoximod and kept an Overweight rating on NewLink with a $26 price target.
10/13/17
BOFA
10/13/17
INITIATION
Target $22
BOFA
Buy
NewLink Genetics initiated with a Buy at BofA/Merrill
BofA/Merrill analyst Ying Huang initiated NewLing Genetics with a Buy and $22 price target saying shares are undervalued. The analyst said Newlink is focused on development of indoximod, an IDO pathway inhibitor, which could become a "backbone" therapy for cancer treatment.
09/25/17
RHCO
09/25/17
NO CHANGE
Target $19
RHCO
Buy
NewLink collaboration with AstraZeneca a validation, says SunTrust
SunTrust analyst Peter Lawson said NewLink Genetics' (NLNK) newly-announced collaboration with AstraZeneca (AZN) is the first "big pharma" partnership for NewLink's lead IDO pathway inhibitor. The deal adds external validation to an asset that is "trading at a fraction" of Incyte's IDO, said Lawson, who keeps a Buy rating and $19 price target on NewLink shares.

TODAY'S FREE FLY STORIES

SAGE

Sage Therapeutics

$61.43

0.08 (0.13%)

14:51
10/17/17
10/17
14:51
10/17/17
14:51
Conference/Events
Sage Therapeutics management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

S

Sprint

$7.10

-0.05 (-0.70%)

14:50
10/17/17
10/17
14:50
10/17/17
14:50
Options
$7M put buyer in Sprint »

$7M put buyer in Sprint.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 16

    May

IBM

IBM

$146.51

-0.32 (-0.22%)

14:49
10/17/17
10/17
14:49
10/17/17
14:49
Options
IBM options imply 5.5% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 22

    Oct

  • 15

    Nov

STZ

Constellation Brands, also tag STZ.B

$212.29

1.84 (0.87%)

14:46
10/17/17
10/17
14:46
10/17/17
14:46
Conference/Events
Constellation Brands, also tag STZ.B management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

SVU

Supervalu

$18.90

0.085 (0.45%)

14:40
10/17/17
10/17
14:40
10/17/17
14:40
Options
Short-term call buying in SuperValu as shares slip into earnings »

Short-term call buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

HES

Hess Corp.

$45.67

-0.37 (-0.80%)

14:30
10/17/17
10/17
14:30
10/17/17
14:30
Options
Hefty spread in Hess as a bullish position is adjusted »

Hefty spread in Hess as a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

DAL

Delta Air Lines

$52.91

-0.71 (-1.32%)

, MSG

Madison Square Garden

$215.84

-1.91 (-0.88%)

14:27
10/17/17
10/17
14:27
10/17/17
14:27
Hot Stocks
Delta expands MSG, MSG Networks partnership »

Delta (DAL) has renewed…

DAL

Delta Air Lines

$52.91

-0.71 (-1.32%)

MSG

Madison Square Garden

$215.84

-1.91 (-0.88%)

MSGN

MSG Networks

$21.03

0.275 (1.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

MOH

Molina Healthcare

$61.64

1.78 (2.97%)

, UNH

UnitedHealth

$205.36

12.16 (6.29%)

14:27
10/17/17
10/17
14:27
10/17/17
14:27
Periodicals
Senator says bipartisan deal reached to stabilize ObamaCare, The Hill reports »

Republican Senator Lamar…

MOH

Molina Healthcare

$61.64

1.78 (2.97%)

UNH

UnitedHealth

$205.36

12.16 (6.29%)

CNC

Centene

$93.61

2.6901 (2.96%)

WCG

WellCare

$173.81

5.89 (3.51%)

CI

Cigna

$188.26

3.27 (1.77%)

ANTM

Anthem

$189.00

5.24 (2.85%)

HNT

Health Net

HUM

Humana

$241.96

4.785 (2.02%)

AET

Aetna

$155.62

4.18 (2.76%)

THC

Tenet

$13.31

0.4 (3.10%)

UHS

Universal Health

$108.19

2.59 (2.45%)

LPNT

LifePoint

$55.80

0.8 (1.45%)

HCA

HCA Healthcare

$77.14

1.95 (2.59%)

CYH

Community Health

$6.13

0.23 (3.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 24

    Oct

  • 25

    Oct

  • 31

    Oct

  • 02

    Nov

  • 02

    Nov

  • 06

    Nov

  • 08

    Nov

14:25
10/17/17
10/17
14:25
10/17/17
14:25
General news
Fed discount rate meeting minutes: 11 of 12 Banks voted for an unchanged »

Fed discount rate meeting…

ORI

Old Republic

$19.53

-0.24 (-1.21%)

14:21
10/17/17
10/17
14:21
10/17/17
14:21
Hot Stocks
Breaking Hot Stocks news story on Old Republic »

Old Republic trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTN

Vail Resorts

$218.22

1.7975 (0.83%)

14:20
10/17/17
10/17
14:20
10/17/17
14:20
Options
Call buyers in Vail Resorts as shares see strength »

Call buyers in Vail…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

SVU

Supervalu

$18.77

-0.04 (-0.21%)

14:18
10/17/17
10/17
14:18
10/17/17
14:18
Technical Analysis
Technical Earnings Preview: Supervalu at multi-year lows ahead of results »

The stock has been in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

$NSD

NASDAQ Market Internals

14:17
10/17/17
10/17
14:17
10/17/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

$39.76

0.09 (0.23%)

, NVDA

Nvidia

$197.93

3.34 (1.72%)

14:16
10/17/17
10/17
14:16
10/17/17
14:16
Periodicals
Intel unveils new family of chips to take on Nvidia in AI, The Verge says »

Intel (INTC) has unveiled…

INTC

Intel

$39.76

0.09 (0.23%)

NVDA

Nvidia

$197.93

3.34 (1.72%)

SFTBF

SoftBank

$89.80

0.9 (1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 18

    Oct

  • 19

    Oct

  • 22

    Oct

  • 23

    Oct

  • 30

    Oct

  • 01

    Nov

$NYE

NYSE Market Internals

14:16
10/17/17
10/17
14:16
10/17/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORI

Old Republic

$19.53

-0.245 (-1.24%)

14:11
10/17/17
10/17
14:11
10/17/17
14:11
Hot Stocks
Old Republic says Q3 to include operating charges of $150M »

Old Republic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NAVI

Navient

$11.73

0.11 (0.95%)

14:10
10/17/17
10/17
14:10
10/17/17
14:10
Options
Call buyers in Navient ahead of earnings »

Call buyers in Navient…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

UNP

Union Pacific

$110.09

-2 (-1.78%)

14:08
10/17/17
10/17
14:08
10/17/17
14:08
Periodicals
Breaking Periodicals news story on Union Pacific »

Union Pacific initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

PACW

PacWest Bancorp

$48.09

0.13 (0.27%)

14:05
10/17/17
10/17
14:05
10/17/17
14:05
Downgrade
PacWest Bancorp rating change  »

PacWest Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 09

    Nov

  • 13

    Nov

  • 14

    Nov

MOH

Molina Healthcare

$60.74

0.88 (1.47%)

, UNH

UnitedHealth

$204.93

11.73 (6.07%)

14:01
10/17/17
10/17
14:01
10/17/17
14:01
Periodicals
Senator Alexander says deal reached to shore up ACA markets, Bloomberg says »

Bloomberg cites Senator…

MOH

Molina Healthcare

$60.74

0.88 (1.47%)

UNH

UnitedHealth

$204.93

11.73 (6.07%)

CNC

Centene

$92.84

1.92 (2.11%)

WCG

WellCare

$172.72

4.8 (2.86%)

CI

Cigna

$187.49

2.5 (1.35%)

ANTM

Anthem

$187.60

3.8392 (2.09%)

HNT

Health Net

HUM

Humana

$241.08

3.905 (1.65%)

AET

Aetna

$155.17

3.7303 (2.46%)

HCA

HCA Healthcare

$75.63

0.44 (0.59%)

CYH

Community Health

$5.97

0.065 (1.10%)

THC

Tenet

$12.79

-0.12 (-0.93%)

UHS

Universal Health

$106.78

1.18 (1.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 24

    Oct

  • 25

    Oct

  • 31

    Oct

  • 02

    Nov

  • 02

    Nov

  • 06

    Nov

  • 08

    Nov

ORI

Old Republic

$19.54

-0.23 (-1.16%)

14:01
10/17/17
10/17
14:01
10/17/17
14:01
Hot Stocks
Breaking Hot Stocks news story on Old Republic »

Old Republic trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DE

Deere

$128.76

1.035 (0.81%)

14:00
10/17/17
10/17
14:00
10/17/17
14:00
Hot Stocks
Deere wins trademark lawsuit against FIMCO »

U.S. District Court in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

XLF

Financial Select Sector

$26.13

-0.17 (-0.65%)

14:00
10/17/17
10/17
14:00
10/17/17
14:00
Options
Whale of a trade in SPDR Financial ETF expresses a defensive view »

Whale of a trade in SPDR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,006.34

3.4 (0.34%)

13:47
10/17/17
10/17
13:47
10/17/17
13:47
Periodicals
Amazon inks deals with apartment landlords for lockers, WSJ reports »

Amazon.com has signed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 22

    Oct

  • 26

    Oct

WMT

Wal-Mart

$85.81

0.065 (0.08%)

13:41
10/17/17
10/17
13:41
10/17/17
13:41
Periodicals
Wal-Mart's Lore: Company plans to acquire more startups, TechCrunch reports »

Wal-Mart eCommerce CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 16

    Nov

  • 21

    Nov

  • 20

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.